The NIH has funded a $4 million study to investigate why weight returns after stopping GLP-1 receptor agonist medications, with investigators at UTHealth Houston leading the work. The research targets a core clinical problem for obesity care: the rebound phenomenon that undermines long-term outcomes when therapy ends. The project underscores the shift from efficacy-only trials to mechanistic work on durability and metabolic set-point recovery in anti-obesity therapeutics.